%0 Journal Article
%A Müller, Daniel J
%A Freitag, Christine M
%A Heilbronner, Urs
%A Nöthen, Markus M
%A Perneczky, Robert
%A Rietschel, Marcella
%A Schulte, Eva C
%A Deckert, Jürgen
%T Genetisch informierte Therapie in der Psychiatrie: neue Dynamik durch APOE und Antikörpertherapie der Alzheimer-Krankheit  -  Genetically informed treatment in psychiatry: new dynamics through APOE and antibody treatment of Alzheimer's disease
%J Der Nervenarzt
%V 97
%N 1
%@ 0028-2804
%C Heidelberg
%I Springer
%M DZNE-2026-00075
%P 82 - 85
%D 2026
%X The European Medicines Agency has recommended testing for the ApoE-genotype prior to treatment of Alzheimer's disease with Lecanemab. The drug approval is limited to patients who are not homozygous for the ApoE epsilon 4 allele. This is to reduce the risk of undesired adverse effects in the patients treated with Lecanemab. With this recommendation for the first time a psychiatric therapy will be genetically informed.
%K Alzheimer Disease: genetics
%K Alzheimer Disease: drug therapy
%K Alzheimer Disease: diagnosis
%K Humans
%K Antibodies, Monoclonal, Humanized: therapeutic use
%K Antibodies, Monoclonal, Humanized: adverse effects
%K Genetic Testing: methods
%K Genetic Predisposition to Disease: genetics
%K Apolipoproteins E: genetics
%K ApoE-genotype (Other)
%K Adverse effects (Other)
%K Alzheimer disease (Other)
%K Lecanemab (Other)
%K Medication safety (Other)
%K Antibodies, Monoclonal, Humanized (NLM Chemicals)
%K Apolipoproteins E (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40548968
%R 10.1007/s00115-025-01839-1
%U https://pub.dzne.de/record/284032